Stem-Cell Mobilization Booster Wins FDA Approval for Multiple Myeloma

(MedPage Today) -- The FDA has approved the CXCR4 antagonist motixafortide (Aphexda) for use with filgrastim (Neupogen) to mobilize stem cells for autologous transplantation in multiple myeloma, BioLineRx announced on Monday. Recent advances in...
Source: MedPage Today Surgery - Category: Surgery Source Type: news